Cholestatic liver disease

24,988views

00:00 / 00:00

High Yield Notes

27 pages

Flashcards

Cholestatic liver disease

of complete

Questions

USMLE® Step 1 style questions USMLE

of complete

A 57-year-old man comes to his primary care physician for evaluation of abdominal pain and fatigue. His symptoms began 4 months ago and have progressively worsened. In addition, he reports a 5 kg (11 lb) unintentional weight loss since symptom onset. The patient often wakes up at night drenched in sweat. Past medical history is notable for peripheral vascular disease and alcohol use disorder. The patient has a 40-pack-year smoking history. Physical examination shows jaundice and scleral icterus. Abdominal pain is most prominent in the epigastric region. Laboratory testing reveals the following findings:  
 
Laboratory value  Result
 Total bilirubin  5.2 mg/dL 
 Conjugated bilirubin  4.6 mg/dL 
 Alkaline phosphatase  96 U/L 
 Aspartate transaminase  110 U/L 
 Alanine transaminase  112 U/L 
 Lipase*  95 U/L 
*Normal range: 12-70 U/L   

Which of the following additional findings will be most likely present on this patient’s physical examination?  

External References

First Aid

2024

2023

2022

2021

Acute cholestatic hepatitis

Cholestasis serum markers p. 397

Liver function tests

cholestatic pattern of p. 402

Transcript

Watch video only

For healthy humans, bile usually flows from the liver and into the small intestine, and this is a super important part of digestion and absorption of nutrients.

When there isn’t enough bile flowing between these two, we can say that there’s some sort of cholestasis going on, because chole- means bile and -stasis means inactivity.

This reduction in bile flow can basically be split into two types, hepatocellular cholestasis, where for some reason the hepatocytes aren’t making enough bile, and obstructive cholestasis, where something’s physically blocking bile flow.

For hepatocellular cholestasis, which would be considered a form of intra-hepatic cholestasis since it’s happening inside the liver, a really important culprit is the hormone estrogen.

Estrogen is thought to basically cause the hepatocytes to not be able to pump out bile acids, usually in the form of cholic acid, which is produced when hepatocytes break down cholesterol.

And in this case, hepatocytes literally can’t pump out the cholic acid, because it’s been found that estrogen inhibits the export pump that usually moves the bile acid from the hepatocyte to the bile canaliculi, which leads to the bile ductules and eventually the common hepatic duct.

But bile acids are just one component of bile, right? Wouldn’t the bile still be made, just without the bile acids?

Well, production and secretion of bile acids is a major driving force for the synthesis of bile in the hepatocytes, so when the cells can’t transport the bile acids and so they build up inside the cells, and this is basically a signal to down-regulate bile acid synthesis and excretion of bile altogether, which decreases the total amount of bile production.

When excretion of bile components like conjugated bilirubin are down, but they’re still being conjugated, they also build up along with the bile acids, and eventually, it’s thought that they diffuse or are exocytosed into the interstitial space, where it can access the blood supply.

Since estrogen’s been linked as a primary suspect here, it makes sense that we see hepatocellular cholestasis in situations where estrogen levels might be higher.

Since oral contraceptive pills, or birth control pills, use estrogen and progesterone to stop ovulation, it makes sense that they’ve been linked to developing cholestasis.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Primary biliary cirrhosis" Hepatology (2009)
  6. "To screen or not to screen? Celiac antibodies in liver diseases" World Journal of Gastroenterology (2017)
Elsevier

Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX